The next revolution in precision oncology
We have a bold ambition to combine emerging and disruptive biological, multi-omics, and machine learning technologies to redefine cancer care.
Our goal is to significantly accelerate drug discovery, achieve a noninvasive and highly personalized treatment course for each patient, and improve clinical efficiency and outcomes.
Only about 15% of cancer patients respond to today’s precision oncology treatments. We are introducing the next chapter in oncology - one where medical innovation knows no bounds and the patient response rates are much higher.
Here’s how: By leveraging RNA sequencing data, the synthetic lethality approach, and deep multi-omics analyses, we provide unique, clinically relevant insights that empower the pharma industry to develop better drugs, repurpose existing drugs, and optimize the overall cost of development. We also help oncologists pinpoint the therapeutic option most likely to elicit a treatment response in each patient.
Accelerating drug development pipelines through better patient stratification and combination matching
Translating expression data into clinical insights by offering superior transcriptomic sensitivity signatures
Significantly increasing patient response rates with AI-driven optimal treatment decisions
The world's first and only pan-cancer response predictor
Meet Enlight – a proprietary, machine learning-powered, deep multi-omics tumor analysis platform that translates cancer big data into actionable molecular signatures.
Powered by an unsupervised and indication-agnostic approach, Enlight unleashes the true power of RNA sequencing. It offers response prediction and drug target identification capabilities across an extensive array of cancer types and therapies.
Enlight's accuracy and efficacy has been demonstrated by strong published evidence.
Improved biomarkers for drug trials
Expanded indications for existing drugs
3X increase in patient response rate
Identification of novel drug targets
Optimal choice of combination therapies
With highly accurate predictive pan-cancer machine learning algorithms, Enlight helps predict new drug response, extend indications of existing drugs, and repurpose failed drugs. It helps achieve better patient stratification and optimize drug development from its early stages. Enlight’s secret is in its ability to create genetic interaction maps surrounding the known drug targets. Based on these maps, accurate predictions can be made way before large drug and indication-specific datasets are available.
The proprietary Enlight Matching Score (EMS) provides oncologists and other healthcare professionals with clear, intuitive, and effective treatment priorities. EMS is designed to help improve each patient’s outcome, even in the most challenging cancer cases.
The approach used by Enlight has been validated in a retrospective analysis of 1,000+ patients who received immunotherapy or targeted therapy, which demonstrated that treatments with a high EMS are three times more likely than standard cancer care to elicit response.
Our collaborations leverage combined resources, technology, and know-how in pursuit of a common goal – shaping the future of cancer medicine. Our research collaborations leverage Enlight to study disease mechanisms, extending Enlight’s abilities by incorporating novel sequencing technologies such as single-cell and liquid-based sequencing. Our pharma and biotech collaborations use Enlight to improve clinical programs. Our collaborations with NGS labs help develop and validate novel transcriptomic and multi-omic biomarkers.
Our publications reflect the latest developments and findings at the intersection of precision oncology and artificial intelligence, as well as our commitment to promoting research for the benefit of those battling cancer.
Professor J. Silvio Gutkind joins Pangea’s Scientific Advisory Board
Leading researcher and NAM member to contribute to Pangea
Cell publishes article co-authored by Pangea
On Precision Oncology via the Tumor Transcriptome
Our Company DNA ...and RNA
Founded in 2018, Pangea is a venture-backed life science startup that is transforming the way cancer is treated. Day in and day out, we work hard to build on genomic medicine, which has powered the recent advances in precision oncology and cancer care. Combining machine learning and RNA analysis, we are mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world.
Our company DNA is determination, collaboration, and an insatiable thirst for innovation.
Our company RNA is our researchers, executive team, and employees – who bring our message to the world.
Eytan Ruppin, MD, PhD
Eytan is Chief of the Cancer Data Science Lab at the NCI. Prior to that, he was Director of the University of Maryland’s Center for Bioinformatics and Computational Biology, where he also served as a professor of computer science.
Eytan has co-founded a number of precision medicine and cancer drug discovery startups, including Metabomed, Medaware, and Pangea Biomed. He is a member of the editorial boards of EMBO Reports and Molecular Systems Biology, and a fellow of the International Society for Computational Biology. His recent research focuses on developing new computational approaches for synthetic lethal and transcriptomics-based precision oncology and immunotherapy.
Eytan received his MD and PhD in computer science from Tel Aviv University, where he also served as a professor of computer science and medicine.
Ze’ev Ronai, PhD
Ze’ev is the Director of the NCI Cancer Center at Sanford Burnham Prebys Discovery Institute in La Jolla, California. Prior to his appointment as director, he served as deputy director and program director. Ze’ev is an expert in cancer biology, with over 300 peer-reviewed publications, reviews and book chapters to his name, as well as a recipient of the Outstanding Investigator Award from the NCI and the Lifetime Achievement Award from the Society of Melanoma Research. His research interests include studies on stress response, with a focus on ubiquitin ligases in hypoxia and ER stress as they pertain to cancer development, progression, and therapy resistance. His recent studies led to clinical trials and set new paradigms in understanding cancer biology.
Ze’ev holds a PhD in tumor immunology from Hebrew University in Jerusalem, Israel. Following postdoctoral research at Columbia University, he was tenured at Mount Sinai School of Medicine in New York.
Eyal Gottlieb, MD, PhD
Eyal is the Laura and Isaac Perlmutter Chair of Cancer Research for the Faculty of Medicine at Technion Israel Institute of Technology in Haifa, Israel. He studies the metabolic adaptations that support tumor growth under metabolic stress. Specifically, he explores vulnerabilities induced by the loss of the metabolic tumor suppressors fumarate hydratase (FH) and succinate dehydrogenase (SDH).
Eyal received his BSc in agriculture from Hebrew University, as well as an MSc and a PhD in molecular cell biology from the Weizmann Institute of Science. In 1998, he became an EMBO fellow at the University of Chicago and later became a Leukemia and Lymphoma Society Special Fellow at the University of Pennsylvania. In 2003, he moved to the Cancer Research-UK Beatson Institute in Glasgow and was then appointed as Professor of Molecular Cell Biology at the University of Glasgow in 2009.
Raanan Berger, MD, PhD
Raanan is a senior oncologist and radiotherapist, serving as Director of the Cancer Center at Sheba Medical Center, Israel. In 2006, he established the Riva Koschitzky Oncology Clinical Research Unit at Sheba, the largest center for all-phase oncology clinical trials in Israel, currently conducting over 200 advanced clinical trials. He is also a senior lecturer at Tel Aviv University’s Sackler Medical School, and runs a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis.
Raanan is a member of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), as well as co-author of over 70 peer-reviewed scientific articles. He received his MD and PhD from the Sackler Faculty of Medicine at Tel Aviv University, Israel, and was a postdoctoral fellow at Dana Farber Cancer Institute, Harvard Medical School.
Ezra Cohen, MD, FRCPSC, FASCO
Ezra is an internationally renowned cancer researcher. He serves as co-director of UC San Diego Health’s Precision Immunotherapy Clinic, and as associate director for translational science and the leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He was previously co-director of the Head and Neck Cancer Program at the University of Chicago Comprehensive Cancer Center.
Ezra leads a laboratory that studies novel cancer treatments, including immunotherapy, and has made major contributions to targeted cancer therapies. A frequent speaker at national and international meetings, he has authored over 170 peer-reviewed papers and has been the principal investigator of multiple clinical trials of new drugs for head and neck cancer and other solid tumors.
Ezra earned his medical degree at University of Toronto. He is board certified in medical oncology, and a fellow of the Royal College of Physicians and Surgeons of Canada (FRCPSC), and the American Society of Clinical Oncology (FASCO).
Dan A. Landau, MD, PhD
Dan is a core faculty member at the New York Genome Center. He is also an Associate Professor of Medicine at Weill Cornell Medicine. Previously, he was an instructor of medicine at Harvard Medical School.
Dan’s goal is to devise therapies that directly anticipate and address tumor evolution. He pioneered the study of intratumoral genetic and epigenetic diversity in patient samples to understand cancer evolution in its natural environment.
Dan has received multiple awards, including the 2019 Weill Cornell Department of Medicine Young Investigators Award, a 2018 NIH Director’s New Innovator Award, an ASPIRE Award from The Mark Foundation for Cancer Research, a Stand Up to Cancer Philip A. Sharp Innovation in Collaboration Award, and a Lung Cancer Discovery Award from the American Lung Association. Dan obtained his MD from Tel Aviv University. He then went on to receive his PhD from Paris Diderot University.
Tuvik Beker, PhD
CEO & Board Member
Tuvik is a seasoned entrepreneur, an experienced executive, and a strong technical leader who spent the last twenty years building, scaling, and leading companies in healthcare, financial, and aerospace domains. He is a co-founder of MedAware Ltd. and serves as its Executive Chairman. He holds a BSc in mathematics from Tel Aviv University and a PhD in computational neuroscience from Hebrew University.
Ranit Aharonov, PhD
Ranit is an AI researcher and expert with two decades of hands-on experience. When she was at IBM Research AI, her team developed Project Debater, the first AI system capable of debating humans on complex topics. Previously, she was VP R&D at Rosetta Genomics (NASDAQ: ROSG). Ranit holds a BA in neuroscience from Brandeis University and a PhD in computational neuroscience from Hebrew University.
Emmanuel Elalouf, Pharm.D, MBA
Emmanuel brings more than twenty years of international experience in the biotech startup ecosystem. He held several senior positions, including EVP & COO of VBL Therapeutics (NASDAQ: VBLT), where he led worldwide business development and strategy. Emmanuel holds a Pharm.D from Paris University and an MBA from Northwestern University in Chicago, Ill.
Eyal Schiff, MD
Eyal was Chairman of the Obstetrics Gynecology and Infertility Division at Sheba Medical Center, Israel. He has extensive experience in managing medical organizations with large-scale teams, and as a director and investor in innovative startup companies in the computational biotech and pharma fields.
Omri Amirav-Drory, PhD
Omri is a General Partner and head of NFX Bio. He is a scientist and well-connected leader in biotech who started, invested in, and scaled some of the industry’s most important companies. Omri founded Genome Compiler, which was later acquired by Twist Bioscience under his guidance. He has a BS in biochemistry and molecular biology, and a PhD in biochemistry from Tel Aviv University. Omri was a Fulbright postdoctorate in biochemistry and molecular biology at Stanford University & HHMI.
Eytan M. Stibbe
Eytan is an impact investor and the founder of Vital Capital Fund, whose goal is to improve the wellbeing of low- and middle-income communities. He is a member of the World Economic Forum (WEF) and Bridges Israel advisory committee. Eytan led the seed investment round for Pangea Biomed. In February 2022, he is scheduled to be an astronaut on a private crew that will fly to the International Space Station.
J. Silvio Gutkind, PhD
Silvio is a Professor and Chair of the Department of Pharmacology at UCSD School of Medicine, as well as the Associate Director for Basic Science at Moores Cancer Center. His research team studies the molecular basis of cancer, with an emphasis on basic mechanisms of signal transduction and cell growth control, and their dysregulation in cancer. He has published over 400 original studies in prestigious journals and organized and co-organized national and international meetings and symposia on signal transduction and oral cancer research.
Silvio received his PhD in pharmacy and biochemistry from the University of Buenos Aires, Argentina, and trained as a postdoctoral fellow at the National Institute of Mental Health (NIMH) and the National Cancer Institute (NCI). He was then Chief of the Oral and Pharyngeal Cancer Branch at the National Institute of Dental and Craniofacial Research (NIDCR) until his recruitment to Moores Cancer Center.
Gideon Rechavi, MD, PhD
Gideon is Professor of Hematology and the Djerassi Chair in Oncology at Tel Aviv University. He served as head of the Division of Hematology at Sackler School of Medicine and as head of the Tel Aviv University Cancer Biology Research Center. In 2003, he established the Sheba Cancer Research Center, which he still heads, and since 2016 he has been heading the Wohl Institute for Translational Medicine.
His research interests are RNA epigenetics, transposable genetic elements, and cancer genomics, with special emphasis on pediatric cancer. He has published over 500 articles in prestigious journals. Gideon is an Israel Prize laureate in medical research and has also been awarded the EMET Prize for Genetics and an ERC Advanced Grant. Additionally, he was selected for the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine. Gideon received his MD from Tel Aviv University and PhD from the Weizmann Institute of Science. He is board certified in hematology, pediatrics, and pediatric hematology-oncology.
Keith T. Flaherty, MD
Keith is Director of Clinical Research at Massachusetts General Hospital Cancer Center, and a Professor of Medicine at Harvard Medical School. He has authored or co-authored over 300 peer-reviewed primary research reports on seminal observations that have defined the the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in treating melanoma. He serves as Editor-in-Chief of Clinical Cancer Research.
Keith is a leader in identifying and clinically evaluating de novo and acquired resistance to BRAF inhibitor therapy, work that has implications for the treatment of other malignant diseases. He obtained his MD from Johns Hopkins University in 1997, after which he completed his internship and residency at Brigham and Women’s Hospital in Boston. Keith then completed a fellowship in medical oncology at the Hospital of the University of Pennsylvania. Prior to Mass General, he was an Assistant Professor of Medicine at the University of Pennsylvania School of Medicine and an Adjunct Professor at the Wistar Institute.